Circulating levels of adrenomedullin in patients with Addison's disease before and after corticosteroid treatment

Letizia, Claudio; Cerci,; Centanni, Marco; Toma, De; Subioli,; Scuro,; Scavo,

doi:10.1046/j.1365-2265.1998.00353.x

Cited by 3 publications

(3 citation statements)

References 19 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AM was measured by a specific radioimmunoassay (RIA, Phoenix Pharm Inc., Mountain View, CA, USA) as previously described 15 . The anti-AM antibody crossreacts 100% with human AM-(1-52) but not with rat AM-(1-50), human amylin, human calcitonin gene-related peptide, endothelin-1, a-atrial natriuretic peptide (1-28), and ~-atrial natriuretic peptide.…”

Section: Assaysmentioning

confidence: 99%

High Plasma Levels of Human Chromogranin a and Adrenomedullin in Patients with Pheochromocytoma

Cotesta

Caliumi

Alò

et al. 2005

Tumori

View full text Add to dashboard Cite

Aims and background The aim of our study was to investigate the plasma chromogranin A (CgA) and adrenomedullin (AM) levels in patients with pheochromocytomas. Methods and study design We collected blood samples for measurement of plasma CgA and AM in 21 patients with pheochromocytomas, 43 healthy subjects and 26 patients with solid non-functioning adrenocortical adenomas. In 11 patients with pheochromocytomas plasma CgA and AM were measured again four weeks after tumor removal. CgA and AM were measured by means of a novel solid-phase two-site immunoradiometric assay based on monoclonal antibodies (CgA-RIA CT, CIS bio international) and by a specific radioimmunoassay (RIA, Phoenix Pharm. Inc.), respectively. Results The mean plasma CgA level (±SD) in patients with pheochromocytomas (204 ± 147.9 ng/mL) was significantly higher (P <0.001) than that in healthy subjects (41.6 ± 10.7 ng/mL) and in patients with non-functioning adrenocortical adenomas (47.3 ± 17.6 ng/mL). The mean plasma AM concentration (±SD) in patients with pheochromocytomas (27.5 ± 10.4 pg/mL) was significantly higher (P <0.001) than that in HS (13.8 ± 4.5 pg/mL) and in patients with non-functioning adrenocortical adenomas (16.6 ± 7.3 pg/mL). Plasma CgA levels correlated with plasma AM levels (r = 0.501; P <0.02) and with plasma metanephrine levels (r = 0.738; P <0.0001) in patients with pheochromocytomas. In 11 patients with pheochromocytomas plasma CgA and AM concentrations significantly decreased after tumor removal (P <0.001 for both). Circulating CgA and AM had a sensitivity of 76.2% and 81%, a specificity of 97.7% and 90.7%, and an accuracy of 91% and 88%, respectively. Conclusion This study demonstrates that circulating CgA and AM levels are increased in pheochromocytoma patients compared with healthy subjects and patients with non-functioning adrenocortical adenomas. Moreover, at the time of diagnosis plasma CgA levels correlated with plasma AM levels and with plasma metanephrine levels in all patients with pheochromocytomas. In conclusion, plasma CgA and AM concentrations may represent additional biochemical parameters for clinical monitoring of patients with pheochromocytomas.

show abstract

Section: Assaysmentioning

confidence: 99%

High Plasma Levels of Human Chromogranin a and Adrenomedullin in Patients with Pheochromocytoma

Cotesta

Caliumi

Alò

et al. 2005

Tumori

View full text Add to dashboard Cite

show abstract

“…AM was measured with a specific radioimmunoassay (RIA, PHOENIX PHARM; Inc. Mountain View, CA; USA) as reported (12). The anti-AM antibody cross-reacts at 100% with human AM-( 1-52) but not with rat AM-( 1-50), human amilin, human calcitonin gene related peptide, endothelin-1, a. atrial natriuretic peptide-( 1-28),~atrial natriuretic peptide- (32) or catrial natriuretic peptide- (22).…”

Section: Plasma Adrenomedullin Concentrationsmentioning

confidence: 99%

Significant Changes of Peripheral Perfusion and Plasma Adrenomedullin Levels in N-Acetylcysteine Long Term Treatment of Patients with Sclerodermic Raynaud's Phenomenon

Salsano

Letizia

Proietti

et al. 2005

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The unclear pathogenesis of scleroderma vascular lesions makes treatment of Raynaud's phenomenon (RP) in Systemic Sclerosis (SSc) patients very difficult and a new effective treatment is requested. Recently, a powerful antioxidant agent, the N-acetylcysteine (NAC) has been shown to decrease the frequency and severity of RP in SSc patients. Subsequently, using functional infrared imaging, we showed that a single 1-hour NAC infusion in these patients caused a significant increase of skin temperature. The aim of this study was to demonstrate the efficacy of long term therapy with NAC in an open clinical trial evaluating clinical, instrumental and laboratory parameters. Patients started the treatment receiving for two years, from October to May, intravenous NAC infusions of 15 mg/kg per hour each, for 5 consecutive hours, every two weeks. Before and after each infusion, patients underwent both Laser Doppler perfusion Imaging (LDPI) for the evaluation of the digital perfusion and a blood test to ascertain the plasma adrenomedullin (AM) levels. The NAC infusion increased global hands perfusion and induced a significant decreasing of plasma AM concentrations. Side effects were negligible, easy to control and reversible. Reduction of frequency and severity of RP attacks was recorded. In conclusion, NAC seems to act as an effective vasodilatator in the treatment of RP secondary to SSc and, in addition, it induced significant changes in plasma levels of AM, a potent vasodilator endothelial-derived peptide.

show abstract

“…For example, we do not know how pancreatic AM production is controlled. Glucocorticoids or atrial natriuretic peptide, which promote a decrease and an increase in AM circulating levels, respectively (Letizia et al, 1998;Vesely et al, 1996), may be involved. The vasodilatory effect of AM may also have some influence on insulin secretion by elevating the pancreatic perfusion rate, but this remains to be established in vivo.…”

Section: Future Perspectives Of Adrenomedullin and Pancreasmentioning

confidence: 99%

Adrenomedullin as a pancreatic hormone

López

Cuesta

2002

Microscopy Res & Technique

View full text Add to dashboard Cite

Adrenomedullin (AM) is a multiregulatory peptide which is expressed in a wide range of tissues. In the pancreas, AM was first found in mammals, including man, and its colocalization with the pancreatic polypeptide (PP) was established in islet F cells. In addition, three different AM receptors have been characterized in B-cells. AM has been also located in the pancreatic cells of other vertebrate classes. The frequency and distribution of AM cells vary between different animals; they can be found scattered among the exocrine tissue, in the islets, or in ductal epithelia. The colocalization of AM with other hormones presents different patterns, although in birds, as in mammals, it seems to colocalize only with PP. The best-determined pancreatic AM function is the inhibition of insulin secretion in B-cells, which seems to be linked to a recently discovered binding protein, factor H. In relation to this physiological role, clinical data show that AM is raised in some groups of both types I and II diabetic patients and AM might have triggered the disease in a subset of them. On the other hand, AM pancreatic cells are also involved in the response to septic shock by increasing AM circulating levels. A third putative function is the inhibition of amylase secretion by the exocrine pancreatic cells. AM has been found in embryonic mammalian pancreas from the earliest stages of the development, colocalizing with all pancreatic hormones, although in adults only coexpression with PP is kept. AM may play a role in the growth and morphogenesis of the pancreas.

show abstract

Circulating levels of adrenomedullin in patients with Addison's disease before and after corticosteroid treatment

Cited by 3 publications

References 19 publications

High Plasma Levels of Human Chromogranin a and Adrenomedullin in Patients with Pheochromocytoma

High Plasma Levels of Human Chromogranin a and Adrenomedullin in Patients with Pheochromocytoma

Significant Changes of Peripheral Perfusion and Plasma Adrenomedullin Levels in N-Acetylcysteine Long Term Treatment of Patients with Sclerodermic Raynaud's Phenomenon

Adrenomedullin as a pancreatic hormone

Contact Info

Product

Resources

About